Name: Latest research reports of Ipca Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Motilal Oswal

Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

1495.5000 -14.40 (-0.95%)

NSE Jan 19, 2026 13:09 PM

28.02% Gain from 52W Low

Volume: 76,974

Ipca Laboratories Ltd.

13 Nov 2025

1495.50

-0.95%

Beat on estimates; DF/API drive earnings

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Laboratories (IPCA) delivered slightly better-than-expected revenue in 2QFY26, while EBITDA/PAT beat our estimates by 18%/22%.

Ipca Laboratories Ltd. is trading above all available SMAs